Emerging research is highlighting new approaches that could make cholesterol treatment more convenient for some patients, potentially improving long-term management of cardiovascular disease. Recent studies have examined both a once-daily oral medication, enlicitide (formerly known as Lipfendra), and the twice-yearly injectable therapy inclisiran, with findings suggesting these treatments may help lower low-density lipoprotein (LDL), or "bad," cholesterol while offering alternatives to traditional daily statin therapy.
According to reports from Healthline and other medical news outlets, these therapies are designed to complement, not necessarily replace, existing cholesterol-lowering medications. Researchers and clinicians say expanding treatment options may help improve medication adherence, particularly for patients who struggle with taking daily medications or who require additional LDL cholesterol reduction to lower their cardiovascular risk.
